All In Biotech

Drug Trial Radar · NCT00133003

Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)

Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)

Last checked: Nov 20, 2026Latest source record: Apr 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,022 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,022

Actual

Start

Mar 2003

Primary completion

Jan 2006

Study completion Jan 2006

Sponsor

Lead sponsor
Deutsches Herzzentrum MuenchenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Technical University of Munich
First posted
Aug 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.

Conditions

  • Coronary Disease
  • Angina, Unstable

Interventions

  • AbciximabDrug

    0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute \[maximum, 10 microg/min\] infusion for 12 hours, plus heparin, 70 U/kg of body weight

  • PlaceboDrug

    Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite rate of death, myocardial infarction, and urgent target vessel revascularization within 30 daysTime frame: 30 days

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Instituto Dante Pazzanese de Cardiologia

    São Paulo, Brazil

  • Herz-Zentrum

    Bad Krozingen, Germany

  • Deutsches Herzzentrum Muenchen

    Munich, Germany

  • First Medizinische Klinik, Klinikum rechts der Isar

    Munich, Germany

  • St. Antonius Ziekenhuis Hospital

    Nieuwegein, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.